ストックスクリーナーアプリを入手
9.9522
1.53%
0.1422
前日終値:
$9.81
開ける：
$9.82
24時間の取引高:
13,192
Relative Volume:
0.02
時価総額：
$507.96M
収益：
$85.21M
当期純損益:
$-140.11M
株価収益率:
-3.9578
EPS:
-2.5146
ネットキャッシュフロー:
$-109.62M
1週間 パフォーマンス:
+0.20%
1か月 パフォーマンス:
+19.57%
6か月 パフォーマンス:
+3.00%
1年 パフォーマンス:
+278.71%
1日の値動き範囲:
$9.82
$10.00
1週間の範囲:
$9.49
$10.88
52週間の値動き範囲:
$2.56
$12.34
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
名前
4 D Molecular Therapeutics Inc
セクター
電話
(510) 505-2680
住所
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
9.95 | 500.82M | 85.21M | -140.11M | -109.62M | -2.5146 |
VRTX
Vertex Pharmaceuticals Inc
|
436.05 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.33 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
800.13 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.19 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.52 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2025-11-07 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2025-01-13 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | 開始されました | Morgan Stanley | Underweight |
| 2024-09-23 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | 開始されました | Barclays | Overweight |
| 2024-02-07 | 再開されました | Goldman | Buy |
| 2023-10-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-18 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 開始されました | Chardan Capital Markets | Buy |
| 2023-01-30 | 開始されました | BMO Capital Markets | Outperform |
| 2022-11-18 | 開始されました | H.C. Wainwright | Buy |
| 2022-11-15 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-12 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | 開始されました | Jefferies | Buy |
| 2022-01-04 | 開始されました | SVB Leerink | Outperform |
| 2021-01-05 | 開始されました | BofA Securities | Buy |
| 2021-01-05 | 開始されました | Evercore ISI | Outperform |
| 2021-01-05 | 開始されました | Goldman | Neutral |
すべてを表示
4 D Molecular Therapeutics Inc (FDMT) 最新ニュース
Layoff Watch: What is the Moat Score of 4D Molecular Therapeutics Inc2026 Short Interest & AI Based Buy and Sell Signals - baoquankhu1.vn
Janus Henderson (NASDAQ: FDMT) holds 5.25M shares, 10.3% stake in 4D Molecular - Stock Titan
Investment Analysts’ Recent Ratings Changes for 4D Molecular Therapeutics (FDMT) - Defense World
JPMorgan Chase & Co. Has $4.46 Million Stock Holdings in 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A. - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Receives Buy Rating from Jefferies Financial Group - Defense World
4D Molecular Therapeutics Inc (FDMT) Stock Price Quote Today & Current Price Chart - Capital.com
4D Molecular Therapeutics Consolidates Financial Leadership Under New Role - TipRanks
FDMT SEC Filings4D Molecular Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Trade 4D Molecular Therapeutics IncFDMT CFD - Capital.com
4D Molecular Therapeutics appoints Kristian Humer as Principal Accounting Officer - TradingView
4D Molecular Therapeutics (NASDAQ: FDMT) elevates CFO Kristian Humer to Principal Accounting Officer - Stock Titan
4D Molecular Therapeutics' (FDMT) "Buy" Rating Reaffirmed at Jefferies Financial Group - MarketBeat
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $32.71 Consensus Target Price from Analysts - Defense World
4D Molecular Therapeutics, Inc. Announces Executive Changes, Effective March 25, 2026 - marketscreener.com
4D Molecular Therapeutics Inc : Jefferies Ass - Moomoo
CEO at 4D Molecular (NASDAQ: FDMT) awarded 750K stock options - Stock Titan
4D Molecular (NASDAQ: FDMT) awards 217,000 stock options to CLO - stocktitan.net
4D Molecular (NASDAQ: FDMT) awards 219,000 stock options to company officer - Stock Titan
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Vanguard amendment shows 0 shares of 4D Molecular (NASDAQ: FDMT) - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Trading 8.7% HigherHere's Why - MarketBeat
VP Gupta of 4d molecular sold $3357 in FDMT stock - Investing.com UK
4D Molecular (NASDAQ: FDMT) VP uses share sale to cover taxes - Stock Titan
Research Analysts Issue Forecasts for FDMT FY2030 Earnings - Defense World
HC Wainwright Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail
4D Molecular Therapeutics (NASDAQ:FDMT) Raised to "Hold" at Wall Street Zen - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Raised to “Hold” at Wall Street Zen - Defense World
4D Molecular Therapeutics (FDMT) Receives a Hold from Cantor Fitzgerald - The Globe and Mail
4D Molecular Therapeutics' (FDMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
4D Molecular Therapeutics’ (FDMT) Buy Rating Reaffirmed at Chardan Capital - Defense World
Reimbursement and Pricing Pressures Threaten Commercial Outlook for 4D Molecular Therapeutics’ Gene Therapies - TipRanks
4D Molecular Therapeutics (FDMT) Q4 Profit Challenges Longstanding Loss Narrative - simplywall.st
4D Molecular Therapeutics (NASDAQ:FDMT) Given New $35.00 Price Target at Royal Bank Of Canada - MarketBeat
4D Molecular Therapeutics (FDMT): RBC Capital Raises Price Targe - GuruFocus
Chardan Capital Reiterates "Buy" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - MarketBeat
RBC Raises Price Target on 4D Molecular Therapeutics to $35 From $32, Keeps Outperform, Speculative Risk - marketscreener.com
4D Molecular Therapeutics (FDMT) Reports 2025 Financial Results, Advances 4D-150 Wet AMD Phase 3 Trials, and Extends Cash Runway Into 2028 - Minichart
4D Molecular Therapeutics, Inc. 2025 Annual Report: Innovative AAV Gene Therapy Pipeline for Retinal and Pulmonary Diseases - Minichart
4D Molecular Therapeutics, Inc. (FDMT) Q4 Results Surpass Forecasts for Earnings and Revenue - Bitget
4D Molecular Therapeutics, Inc. (FDMT) Q4 earnings and revenues beat estimates - MSN
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
4D Molecular Therapeutics : 4DMT Corporate Presentation – March 2026 (dfceb5) - marketscreener.com
4D Molecular Therapeutics 10-K: $85.2M collaboration revenue; improved net loss $140.1M - TradingView
4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results, Beats Estimates By $0.96 EPS - MarketBeat
4D Molecular Therapeutics (FDMT) details retina and lung gene therapy pipeline in 10-K - Stock Titan
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times
4D Molecular Therapeutics (NASDAQ: FDMT) posts 2025 results, inks Otsuka deal, extends cash runway - Stock Titan
4 D Molecular Therapeutics Inc (FDMT) 財務データ
収益
当期純利益
現金流量
EPS
0.62%
0.89%
大文字化:
|
ボリューム (24 時間):